» Articles » PMID: 843423

Fate of [14C]-bumetanide in Man

Overview
Specialty Pharmacology
Date 1977 Feb 1
PMID 843423
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

1. The fate of bumetanide was studied in four healthy volunteers both after intravenous oral administration of [14C]-bumetanide (0.5 mg). 2. The absorption of oral [14C]-bumetanide was rapid (absorption half-life 0.61 h) and complete with a urinary recovery of about 80% of the intravenous or oral dose during 48 h. 3. The elimination of [14C]-bumetanide was rapid with a half-life of elimination (T 1/2 beta) of 1.5 h. 4. Protein bound fraction of [14C]-bumetanide in plasma was 95%. No bumetanide was found in red blood cells. 5. Four metabolites of [14C]-bumetanide were found in urine. Together they accounted for about one third of the radio-activity excreted into urine during the first 6 h after the administration of the drug. 6. Bumetanide is rapidly and completely absorbed from the gastrointestinal tract, bound extensively to plasma proteins, metabolized to some extent and excreted rapidly, principally into urine.

Citing Articles

Hydroxyapatite Nanorods Based Drug Delivery Systems for Bumetanide and Meloxicam, Poorly Water Soluble Active Principles.

Friuli V, Maggi L, Bruni G, Caso F, Bini M Nanomaterials (Basel). 2024; 14(1).

PMID: 38202568 PMC: 10780568. DOI: 10.3390/nano14010113.


Contribution of Monocarboxylate Transporter 6 to the Pharmacokinetics and Pharmacodynamics of Bumetanide in Mice.

Jones R, Ruszaj D, Parker M, Morris M Drug Metab Dispos. 2020; 48(9):788-795.

PMID: 32587098 PMC: 7469248. DOI: 10.1124/dmd.120.000068.


Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome.

Deidda G, Parrini M, Naskar S, Bozarth I, Contestabile A, Cancedda L Nat Med. 2015; 21(4):318-26.

PMID: 25774849 DOI: 10.1038/nm.3827.


Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures.

Puskarjov M, Kahle K, Ruusuvuori E, Kaila K Epilepsia. 2014; 55(6):806-18.

PMID: 24802699 PMC: 4284054. DOI: 10.1111/epi.12620.


Individualization of a pharmacokinetic model by fractional and nonlinear fit improvement.

Popovic J, Posa M, Popovic K, Popovic D, Milosevic N, Tepavcevic V Eur J Drug Metab Pharmacokinet. 2012; 38(1):69-76.

PMID: 22618469 DOI: 10.1007/s13318-012-0097-6.


References
1.
FEIT P, ROHOLT K, Sorensen H . GLC determination and urinary recovery of bumetanide in healthy volunteers. J Pharm Sci. 1973; 62(3):375-9. DOI: 10.1002/jps.2600620304. View

2.
Magnussen M, EILERTSEN E . Proceedings: Species differences in the diuretic activity and metabolism of bumetanide. Naunyn Schmiedebergs Arch Pharmacol. 1974; 282(Suppl):suppl 282:R61. View

3.
OLESEN K, Sigurd B, Steiness E, Leth A . Bumetanide, a new potent diuretic. A clinical evaluation in congestive heart failure. Acta Med Scand. 1973; 193(1-2):119-31. View

4.
Loo J, RIEGELMAN S . New method for calculating the intrinsic absorption rate of drugs. J Pharm Sci. 1968; 57(6):918-28. DOI: 10.1002/jps.2600570602. View

5.
Walker S . The influence of protein binding on the excretion of some sulphanilamidopyrimidines in man. J Pharm Pharmacol. 1970; 22(8):574-7. DOI: 10.1111/j.2042-7158.1970.tb10573.x. View